Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP
Por:
Bazarbachi, A, Galimard, JE, Abou Dalle, I, Labopin, M, Sanz, J, Huang, H, Mayer, J, Solano, C, Lioure, B, Griskevicius, L, Maertens, J, Itälä-Remes, M, Kaare, A, Gallego-Hernanz, MP, Bug, G, Ribera, JM, Gadisseur, A, Schmid, C, Kwon, M, Poiré, X, Coccia, P, Chacon, MJ, Baron, F, Craddock, C, Brissot, E, Nagler, A, Ciceri, F and Mohty, M
Publicada:
1 mar 2026
Ahead of Print:
1 dic 2025
Resumen:
Acute myeloid leukemia (AML) includes genetically defined subsets. In allogeneic hematopoietic cell transplantation (allo-HCT), the frequency and prognosis of gene-gene interactions may differ from those of patients treated with chemotherapy alone. In this study, adult patients (N = 952) with AML allografted between 2015 and 2023, with available next generation sequencing (NGS) at diagnosis were included. Most frequent mutations were DNMT3A (24%), FLT3-ITD (21%), NPM1 (21%), RUNX1 (16%), NRAS (16%), TET2 (14%), and IDH2 (12%). Multiple correspondence analysis identified distinct groups of co-occurring mutations. Outcome analysis was performed on 646 AML patients allografted in first complete remission (CR1). Six non-overlapping groups were constructed: 1) TP53 mutation (N = 47); 2) NPM1 mutation (N = 129); 3) FLT3-ITD and/or DNMT3A mutation (N = 128); 4) SRSF2 and/or ASXL1 and/or RUNX1 mutation (SAR group) (N = 132); 5) IDH1 and/or IDH2 and/or TET2 mutation (N = 43); and 6) all ten genes unmutated (N = 167). In multivariable analysis, TP53 mutation, adverse karyotype, and age negatively affected leukemia-free survival (LFS) and overall survival (OS). OS was additionally negatively affected when the ten genes were unmutated. Notably, outcomes were excellent for SAR mutations (2-year LFS 76%, OS 84%), indicating allo-HCT in CR1 can overcome their adverse risk at diagnosis.
Filiaciones:
Bazarbachi, A:
Amer Univ, Beirut Med Ctr, Dept Internal Med, Bone Marrow Transplantat Program, Beirut, Lebanon
Galimard, JE:
Sorbonne Univ, St Antoine Hosp, AP HP,EBMT Paris Study Unit, Rheumatol Dept,INSERM,UMRs 938, F-75012 Paris, France
Abou Dalle, I:
Amer Univ, Beirut Med Ctr, Dept Internal Med, Bone Marrow Transplantat Program, Beirut, Lebanon
Labopin, M:
Sorbonne Univ, St Antoine Hosp, AP HP,EBMT Paris Study Unit, Rheumatol Dept,INSERM,UMRs 938, F-75012 Paris, France
Sanz, J:
Univ Valencia, Hosp Univ & Politecn La Fe, Hematol Dept, CIBERONC,Valencia Dept Med,Inst Carlos III, Madrid, Spain
Huang, H:
Zhejiang Univ, Affiliated Hosp 1, Sch Med, Kunming, Peoples R China
Mayer, J:
Univ Hosp Brno, Brno, Czech Republic
Solano, C:
Univ Valencia, Hosp Clin Univ, INCLIVA, Valencia, Spain
Lioure, B:
Hop Univ Strasbourg, Hematol Oncol Dept, Strasbourg, France
Griskevicius, L:
Vilnius Univ Hosp, Santaros Klin, Vilnius, Lithuania
Vilnius Univ, Vilnius, France
Maertens, J:
Univ Hosp Gasthuisberg, Leuven, Belgium
Itälä-Remes, M:
Turku Univ Hosp, Turku, Finland
Kaare, A:
Tartu Univ Hosp, Tartu, Estonia
Gallego-Hernanz, MP:
Univ Hosp Poitiers, Hematol Oncol & Cellular Therapy Dept, Poitiers, France
Bug, G:
Goethe Univ Frankfurt, Frankfurt Main, Germany
:
ICO Hosp Univ Germans Trias i Pujol, Josep Carreras Res Inst, Badalona, Spain
Gadisseur, A:
Antwerp Univ Hosp UZA, Antwerp, Belgium
Schmid, C:
Augsburg Univ Hosp, Augsburg, Germany
Med Fac, Augsburg, Germany
Kwon, M:
Hosp Gen Univ Gregorio Maranon, Dept Hematol, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
Poiré, X:
Clin Univ St Luc, Brussels, Belgium
Coccia, P:
Azienda Osped Riuniti Ancona, Ancona, Italy
Chacon, MJ:
Hosp Univ Virgen de Las Nieves, Granada, Spain
Craddock, C:
Queen Elizabeth Hosp, Blood & Marrow Transplant Unit, Birmingham, England
Brissot, E:
Hop St Antoine, Serv Hematol & Malad Sang, Paris, France
Nagler, A:
Chaim Sheba Med Ctr, Hematol Div, Tel Hashomer, Israel
Ciceri, F:
Univ Vita Salute, IRCCS Osped San Raffaele, Haematol, Milan, Italy
BMT, Milan, Italy
Mohty, M:
Sorbonne Univ, St Antoine Hosp, AP HP, Rheumatol Dept,Inserm,UMRs 938, Paris, France
Green Accepted
|